More about
Von Hippel-Lindau Disease
News
November 24, 2021
2 min read
Save
Belzutifan active in von Hippel-Lindau disease-associated renal cell carcinoma
Belzutifan demonstrated clinical efficacy among patients with von Hippel-Lindau disease-associated renal cell carcinoma, according to results of a phase 2 study published in The New England Journal of Medicine.
News
August 13, 2021
1 min read
Save
FDA approves Welireg for von Hippel-Lindau disease-associated cancers
The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease.
News
March 16, 2021
1 min read
Save
FDA grants priority review to belzutifan for renal cell carcinoma subset
The FDA granted priority review to belzutifan for treatment of certain patients with renal cell carcinoma.
News
July 29, 2020
1 min read
Save
FDA grants breakthrough therapy designation to MK-6482 for renal cell carcinoma subtype
The FDA granted breakthrough therapy designation to MK-6482 for the treatment of certain patients with von Hippel-Lindau disease-associated renal cell carcinoma, according to a press release from the agent’s manufacturer.